Shattuck Labs, Inc. (STTK): Total Liabilities
$8.64M
As of 2025-12-31
$9.53M
As of 2026-06-30
-33.3%
3-year compound annual growth
-26.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.64M | -24.4% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $11.42M | -23.1% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $14.86M | -49.1% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $29.17M | +8.8% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $26.80M | -31.5% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $39.13M | +28.5% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $30.45M | n/a | 2021-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $8.64M | -24.4% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.99M | +10.1% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $29.63M | +5.4% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $15.74M | +48.8% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $2.45M | +17.9% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $5.05M | -18.9% |
| Rallybio Corp (RLYB) | 2025-12-31 | $4.30M | -33.3% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $4.11M | -57.1% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.59M | +24.9% |
Compare STTK, SXTP, DARE, RFL side by side · Screen every company in Pharmaceutical Preparations ↗